Action of Myc in vivo - Proliferation and apoptosis

Current Opinion in Genetics and Development

Volumn 10, Issue 1, 2000, Pages 100-105

  Pelengaris, Stella ^a   Rudolph, Bettina ^b   Littlewood, Trevor ^c  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b DeveloGen AG   (Germany)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN;

APOPTOSIS; CARCINOGENESIS; CELL PROLIFERATION; DIABETES MELLITUS; LYMPHOMA; ONCOGENE C MYC; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; SKIN CARCINOGENESIS; TUMOR GROWTH;

EID: 0033994207     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(99)00046-5     Document Type: Review

References (33)

1. Amati B., Land H. Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death. Curr Opin Genet Dev. 4:1994;102-108.
2. Bouchard C., Staller P., Eilers M. Control of cell proliferation by Myc. Trends Cell Biol. 8:1998;202-206.
3. Desbarats L., Schneider A., Muller D., Burgin A., Eilers M. Myc: a single gene controls both proliferation and apoptosis in mammalian cells. Experientia. 52:1996;1123-1129.
4. Eilers M. Control of cell proliferation by Myc family genes. Mol Cell. 9:1999;1-6.
5. Evan G.I., Littlewood T.D. The role of c-myc in cell growth. Curr Opin Genet Dev. 3:1993;44-49.
6. Evan G., Harrington E., Fanidi A., Land H., Amati B., Bennett M. Integrated control of cell proliferation and cell death by the c-myc oncogene. Philos Trans R Soc Lond B Biol Sci. 345:1994;269-275.
7. Evan G.I., Brown L., Whyte M., Harrington E. Apoptosis and the cell cycle. Curr Opin Cell Biol. 7:1995;825-834.
8. Evan G., Littlewood T. A matter of life and cell death. Science. 281:1998;1317-1322. A very well written review discussing the propensity for growth-deregulating oncoproteins such as Myc, E1A and E2F, to induce apoptosis and propose the model that c-Myc acts to sensitise cells to a variety of apoptotic triggers rather than acting solely as a death effector. This potent mechanism to limit expansion of neoplastic cells and the cooperation between various oncoproteins are discussed.
9. Prendergast G.C. Mechanisms of apoptosis by c-Myc. Oncogene. 18:1999;2967-2987. A very well written review summarising molecular advances in apoptosis with specific attention made to the mechanisms of apoptosis induced by c-Myc.
10. Steiner P., Rudolph B., Muller D., Eilers M. The functions of Myc in cell cycle progression and apoptosis. Prog Cell Cycle Res. 2:1996;73-82.
11. Eilers M., Schirm S., Bishop J.M. The MYC protein activates transcription of the alpha-prothymosin gene. EMBO J. 10:1991;133-141.
12. Littlewood T.D., Hancock D.C., Danielian P.S., Parker M.G., Evan G.I. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23:1995;1686-1690.
13. Evan G.I., Wyllie A.H., Gilbert C.S., Littlewood T.D., Land H., Brooks M., Waters C.M., Penn L.Z., Hancock D.C. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 69:1992;119-128.
14. Juin P., Hueber A.O., Littlewood T., Evan G. c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev. 13:1999;1367-1381. This elegant in vitro study shows that c-Myc promotes apoptosis of fibroblasts by causing the release of cytochrome c from mitochondria into the cytosol. Cytochrome c release, in itself, however, is not efficient at inducing apoptosis but can cooperate with other triggers of apoptosis such as CD95/Fas and p53. These data provide a mechanism for c-Myc-induced sensitisation to apoptosis.
15. Harrington E.A., Bennett M.R., Fanidi A., Evan G.I. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 13:1994;3286-3295.
16. Marcu K.B., Bossone S.A., Patel A.J. myc function and regulation. Annu Rev Biochem. 61:1992;809-860.
17. Spencer C.A., Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res. 56:1991;1-48.
18. Morgenbesser S.D., DePinho R.A. Use of transgenic mice to study myc family gene function in normal mammalian development and in cancer. Semin Cancer Biol. 5:1994;21-36.
19. Mushinski J.F., Hanley-Hyde J., Rainey G.J., Kuschak T.I., Taylor C., Fluri M., Stevens L.M., Henderson D.W., Mai S. Myc-induced cyclin D2 genomic instability in murine B cell neoplasms. Curr Top Microbiol Immunol. 246:1999;183-189. [Discussion 190-192].
20. Felsher D.W., Bishop J.M. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci USA. 96:1999;3940-3944.
21. Mai S., Hanley-Hyde J., Rainey G.J., Kuschak T.I., Paul J.T., Littlewood T.D., Mischak H., Stevens L.M., Henderson D.W., Mushinski J.K. Chromosomal and extrachromosomal instability of the cyclin D2 gene in induced by Myc overexpression. Neoplasia. 1:1999;241-252.
22. Strasser A., Elefanty A.G., Harris A.W., Cory S. Progenitor tumours from Emu-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival. EMBO J. 15:1996;3823-3834.
23. Strasser A., Harris A.W., Bath M.L., Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature. 348:1990;331-333.
24. Berns A. Turning on tumors to study cancer progression [news]. Nat Med. 5:1999;989-990.
25. Blyth K., Stewart M., Bell M., James C., Evan G., Neil J.C., Cameron E.R. Sensitivity to myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycER™ mice. Oncogene. 2000;. in press.
26. Felsher D.W., Bishop J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 4:1999;199-207. This paper describes the use of the tetracycline regulatory system to conditionally express myc in haematopoietic cells of transgenic mice. Although sustained myc expression during development leads to malignant T cell lymphomas and acute myeloid leukaemias, inactivation of the transgene causes regression of the majority of established tumours. These results show for the first time that, despite the multistep nature of tumourigenesis in haematopoietic lineages, inactivation of a single genetic lesion, myc, is sufficient to reverse malignancy.
27. ™, was targeted to suprabasal keratinocytes of murine epidermis and activation of the chimaeric protein achieved with administration of tamoxifen. The authors describe the phenotype observed following immediate and short-term activation of c-Myc in the epidermis and, perhaps surprisingly, shows that c-Myc alone is sufficient to induce pre-malignant skin lesions (papillomatosis) with profound angiogenesis.
28. Marrack P., Winslow G.M., Choi Y., Scherer M., Pullen A., White J., Kappler J.W. The bacterial and mouse mammary tumor virus superantigens; two different families of proteins with the same functions. Immunol Rev. 131:1993;79-92.
29. Tough D., Sprent J. Turnover of naïve- and memory-phenotype T cells. J Exp Med. 179:1994;1127-1135.
30. Shortman K., Egerton M., Spangrude G.J., Scollary R. The generation and fate of thymocytes. Semin Immunol. 2:1990;3-12.
31. Stewart M., Cameron E., Campbell M., Mcfarlane R., Toth S., Lang K., Onions D., Neil J.C. Conditional expression and oncogenity of c-myc linked to a CD2 gene dominant control region. Int J Cancer. 53:1993;1023-1030.
32. Spanopoulou E., Early A., Elliot J., Crispe N., Ladyman H., Ritter M., Watt S., Grosveld F., Kioussis D. Complex lymphoid and epithelial thymic tumours in Thy1-myc transgenic mice. Nature. 342:1989;185-189.
33. Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S., Palmiter R.D., Brinster R.L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 318:1985;533-538.